Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Toripalimab-tpzi

Placeholder slot
 (TOR-ih-PA-lih-mab)

This page contains brief information about toripalimab-tpzi and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Loqtorzi
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Toripalimab-tpzi is approved to treat:

  • Nasopharyngeal carcinoma (a type of head and neck cancer). It is used:
    • With cisplatin and gemcitabine hydrochloride as the first treatment in adults whose cancer has spread to other parts of the body or has come back in nearby tissues.
    • Alone in adults whose cancer has come back and cannot be removed by surgery or has spread to other parts of the body and has been treated with platinum chemotherapy that did not work or is no longer working.

Toripalimab-tpzi is also being studied in the treatment of other types of cancer.

More About Toripalimab-tpzi

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Clinical Trials Accepting Patients

Find Clinical Trials for Toripalimab-tpzi - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email